CervoMed Management

Management criteria checks 1/4

CervoMed's CEO is John Alam, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is $815.16K, comprised of 58% salary and 42% bonuses, including company stock and options. directly owns 8.85% of the company’s shares, worth $1.62M. The average tenure of the management team and the board of directors is 1.3 years and 1.3 years respectively.

Key information

John Alam

Chief executive officer

US$815.2k

Total compensation

CEO salary percentage58.0%
CEO tenure1.3yrs
CEO ownership8.9%
Management average tenure1.3yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

CervoMed Inc.'s (NASDAQ:CRVO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Nov 19
CervoMed Inc.'s (NASDAQ:CRVO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate

Aug 24
We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate

Companies Like CervoMed (NASDAQ:CRVO) Are In A Position To Invest In Growth

Dec 07
Companies Like CervoMed (NASDAQ:CRVO) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has John Alam's remuneration changed compared to CervoMed's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$12m

Jun 30 2024n/an/a

-US$5m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$815kUS$472k

-US$2m

Sep 30 2023n/an/a

-US$1m

Mar 31 2023n/an/a

-US$5m

Dec 31 2022US$594kUS$450k

-US$6m

Compensation vs Market: John's total compensation ($USD815.16K) is about average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


CEO

John Alam (62 yo)

1.3yrs

Tenure

US$815,155

Compensation

Dr. John J. Alam, M.D. serves as Chief Executive Officer at CervoMed Inc. (Formerly, EIP Pharma, LLC) and also serves as its President since August 2023 and serves as its Director since August 2023. He is...


Leadership Team

NamePositionTenureCompensationOwnership
John Alam
Co-Founder1.3yrsUS$815.16k8.85%
$ 1.6m
Sylvie Gregoire
Co-Founder & Directorno dataUS$376.94k8.85%
$ 1.6m
William Elder
CFO & General Counsel4.3yrsUS$468.35k0.015%
$ 2.8k
Robert Cobuzzi
COO & Director1.3yrsUS$703.12k0.013%
$ 2.4k
Kelly Blackburn
Senior Vice President of Clinical Development6.6yrsUS$465.74k0.17%
$ 30.4k
Mark De Rosch
SVP of Regulatory & Government Affairs & Program Managementless than a yearno datano data
Claudia Ordonez
Senior Vice President of Medical Scienceless than a yearno datano data

1.3yrs

Average Tenure

60yo

Average Age

Experienced Management: CRVO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
John Alam
Co-Founder1.3yrsUS$815.16k8.85%
$ 1.6m
Sylvie Gregoire
Co-Founder & Director1.3yrsUS$376.94k8.85%
$ 1.6m
Robert Cobuzzi
COO & Director1.1yrsUS$703.12k0.013%
$ 2.4k
Joshua Boger
Independent Chair of the Boardless than a yearno data12.81%
$ 2.3m
Jane Hollingsworth
Independent Director4.3yrsUS$82.91k0.011%
$ 2.0k
Jeffrey Cummings
Member Scientific of Advisory Boardno datano datano data
Ole Isacson
Chair of the Scientific Advisory Boardno datano datano data
Lewis Cantley
Member of Scientific Advisory Boardno datano datano data
Frank Zavrl
Independent Director1.3yrsUS$47.76k4.28%
$ 783.7k
Marwan Sabbagh
Independent Non-Executive Director1.3yrsUS$41.15k0%
$ 0
Jeffrey Poulton
Independent Director1.3yrsUS$47.20k0.20%
$ 36.5k
Heidi McBride
Member of Scientific Advisory Boardno datano datano data

1.3yrs

Average Tenure

63yo

Average Age

Experienced Board: CRVO's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 23:47
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CervoMed Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tyler BussianBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity
Daniil GataulinChardan Capital Markets, LLC